• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

古巴慢性肝病患者的健康相关生活质量:真实世界的经验。

Health-related quality of life in Cuban patients with chronic liver disease: A real-world experience.

机构信息

Institute of Gastroenterology, University of Medical Sciences of Havana, Havana, Cuba.

Institute of Gastroenterology, University of Medical Sciences of Havana, Havana, Cuba.

出版信息

Ann Hepatol. 2021 May-Jun;22:100277. doi: 10.1016/j.aohep.2020.10.005. Epub 2020 Oct 29.

DOI:10.1016/j.aohep.2020.10.005
PMID:33130334
Abstract

INTRODUCTION AND OBJECTIVES

Patient-reported outcomes (PROs) are important for comprehensive assessment of chronic liver disease (CLD). Latin America and the Caribbean have a high burden of CLD, but PROs are lacking. We assessed health-related quality of life (HRQL) in Cuban patients with compensated CLD.

MATERIALS AND METHODS

A cross sectional study performed of adult patients with a diagnosis of chronic viral infection B and C (HBV, HCV), non-alcoholic fatty liver diseases (NAFLD) and autoimmune liver diseases (AILD) including autoimmune hepatitis (AIH), primary biliary cholangitis (PBC) and overlap syndrome (AIH+PBC). PROs were collected using: Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F), Work Productivity and Activity-Specific Health Problem (WPAI: SHP), and the Chronic Liver Disease Questionnaire (CLDQ)-disease-specific.

RESULTS

543 patients enrolled, n=91 (HBV), n=188 (HCV), n=221 (NAFLD), n=43 (AILD). Of those with AILD, 22 had AIH, 14 PBC, and 7 overlap AIH/PBC. Mean age was 53.5 years, 64.1% female, 69.2% white, and 58.0% employed. Patients with HCV and AILD had more severe liver disease. A significant impairment in PROs was observed in HCV group whereas the AILD patients had more activity impairment. CLDQ-HRQL scores were significantly lower for patients with NAFLD and AILD compared to HBV. Male gender and exercising ≥90min/week predicted better HRQL. The strongest independent predictors of HRQL impairment were fatigue, abdominal pain, anxiety, and depression (p<0.05).

CONCLUSIONS

HRQL for Cuban patients with compensated CLD differs according to the CLD etiology. Patients with HCV and AILD had the worst PRO scores most likely related to severe underlying liver disease and/or extrahepatic manifestations.

摘要

简介和目的

患者报告的结果(PROs)对于慢性肝病(CLD)的综合评估很重要。拉丁美洲和加勒比地区 CLD 负担沉重,但 PROs 却缺乏。我们评估了古巴代偿性 CLD 患者的健康相关生活质量(HRQL)。

材料和方法

对诊断为慢性乙型和丙型病毒感染(HBV、HCV)、非酒精性脂肪性肝病(NAFLD)和自身免疫性肝病(AILD)的成年患者进行了一项横断面研究,包括自身免疫性肝炎(AIH)、原发性胆汁性胆管炎(PBC)和重叠综合征(AIH+PBC)。使用以下方法收集 PROs:慢性疾病治疗功能评估-疲劳量表(FACIT-F)、工作生产力和活动特异性健康问题量表(WPAI:SHP)和慢性肝病问卷(CLDQ)-疾病特异性。

结果

共纳入 543 例患者,其中 HBV 患者 91 例,HCV 患者 188 例,NAFLD 患者 221 例,AILD 患者 43 例。其中 AILD 患者 22 例为 AIH,14 例为 PBC,7 例为重叠 AIH/PBC。平均年龄为 53.5 岁,女性占 64.1%,白种人占 69.2%,就业者占 58.0%。HCV 和 AILD 患者的肝病更严重。在 HCV 组中观察到 PRO 显著受损,而 AILD 患者的活动受损更严重。与 HBV 相比,NAFLD 和 AILD 患者的 CLDQ-HRQL 评分明显较低。男性性别和每周锻炼≥90 分钟可预测更好的 HRQL。HRQL 受损的最强独立预测因素是疲劳、腹痛、焦虑和抑郁(p<0.05)。

结论

古巴代偿性 CLD 患者的 HRQL 因 CLD 病因而异。HCV 和 AILD 患者的 PRO 评分最差,可能与严重的基础肝病和/或肝外表现有关。

相似文献

1
Health-related quality of life in Cuban patients with chronic liver disease: A real-world experience.古巴慢性肝病患者的健康相关生活质量:真实世界的经验。
Ann Hepatol. 2021 May-Jun;22:100277. doi: 10.1016/j.aohep.2020.10.005. Epub 2020 Oct 29.
2
Clinical and patient-reported outcomes in patients with chronic hepatitis B and C and non-alcoholic fatty liver disease from real-world practices in Saudi Arabia, Turkey and Egypt.沙特阿拉伯、土耳其和埃及真实世界实践中慢性乙型和丙型肝炎及非酒精性脂肪性肝病患者的临床和患者报告结局。
J Viral Hepat. 2024 Jun;31(6):300-308. doi: 10.1111/jvh.13935. Epub 2024 Apr 15.
3
Association of work productivity with clinical and patient-reported factors in patients infected with hepatitis C virus.丙型肝炎病毒感染患者的工作生产力与临床及患者报告因素的关联
J Viral Hepat. 2016 Aug;23(8):623-30. doi: 10.1111/jvh.12528. Epub 2016 Mar 14.
4
Assessment of fatigue and its impact in chronic liver disease.慢性肝脏疾病的疲劳评估及其影响。
J Hepatol. 2024 Oct;81(4):726-742. doi: 10.1016/j.jhep.2024.04.008. Epub 2024 Apr 24.
5
Dynamics and liver disease specific aspects of quality of life among patients with chronic liver disease in Yunnan, China.中国云南慢性肝病患者生活质量的动态变化及肝病特异性方面
Asian Pac J Cancer Prev. 2014;15(12):4765-71. doi: 10.7314/apjcp.2014.15.12.4765.
6
[Assessment of the possible impact of hepatitis viruses on the development and course of autoimmune liver diseases].[评估肝炎病毒对自身免疫性肝病发生发展及病程的可能影响]
Ter Arkh. 2023 Mar 30;95(2):173-178. doi: 10.26442/00403660.2023.02.202113.
7
Neuropsychiatric symptoms in hepatitis C patients resemble those of patients with autoimmune liver disease but are different from those in hepatitis B patients.丙型肝炎患者的神经精神症状与自身免疫性肝病患者相似,但与乙型肝炎患者不同。
J Viral Hepat. 2019 Apr;26(4):422-431. doi: 10.1111/jvh.12979. Epub 2019 Jan 28.
8
Improvement of health-related quality of life and work productivity in chronic hepatitis C patients with early and advanced fibrosis treated with ledipasvir and sofosbuvir.聚乙二醇干扰素α-2a 联合利巴韦林治疗慢性丙型肝炎的病毒学应答预测因素分析
J Hepatol. 2015 Aug;63(2):337-45. doi: 10.1016/j.jhep.2015.03.014. Epub 2015 Mar 17.
9
Patient-reported outcomes in chronic hepatitis C patients with cirrhosis treated with sofosbuvir-containing regimens.索磷布韦方案治疗肝硬化慢性丙型肝炎患者的患者报告结局。
Hepatology. 2014 Jun;59(6):2161-9. doi: 10.1002/hep.27161. Epub 2014 Apr 30.
10
Factors influencing health-related quality of life in chronic liver disease.影响慢性肝病患者健康相关生活质量的因素。
World J Gastroenterol. 2006 Dec 28;12(48):7786-91. doi: 10.3748/wjg.v12.i48.7786.

引用本文的文献

1
Assessment of PBC Pruritus From the ITCH-E Study: Quality of Life, Productivity, and Treatment Experiences.来自ITCH-E研究的原发性胆汁性胆管炎瘙痒评估:生活质量、生产力及治疗体验
Liver Int. 2025 Sep;45(9):e70276. doi: 10.1111/liv.70276.
2
Exploring the link between non-alcoholic fatty liver disease and depression: a systematic review and meta-analysis of bidirectional risk.探索非酒精性脂肪性肝病与抑郁症之间的联系:双向风险的系统评价和荟萃分析
Am J Transl Res. 2025 May 15;17(5):3691-3702. doi: 10.62347/XLVA5738. eCollection 2025.
3
Status and factors influencing health-related quality of life in patients with non-alcoholic fatty liver disease in Hangzhou: a cross-sectional study.
杭州非酒精性脂肪性肝病患者健康相关生活质量的现状及影响因素:一项横断面研究
BMJ Open. 2025 Mar 5;15(3):e088357. doi: 10.1136/bmjopen-2024-088357.
4
Psychological factors and biochemical indicators influencing sleep disturbance of patients with primary biliary cholangitis in China: a cross-sectional survey analysis.影响中国原发性胆汁性胆管炎患者睡眠障碍的心理因素和生化指标:一项横断面调查分析
Front Med (Lausanne). 2024 Oct 3;11:1444473. doi: 10.3389/fmed.2024.1444473. eCollection 2024.
5
A Review of the Systemic Manifestations of Hepatitis B Virus Infection, Hepatitis D Virus, Hepatocellular Carcinoma, and Emerging Therapies.乙型肝炎病毒感染、丁型肝炎病毒、肝细胞癌及新兴疗法的全身表现综述
Gastro Hep Adv. 2023 Jul 17;3(2):276-291. doi: 10.1016/j.gastha.2023.06.014. eCollection 2024.
6
Non-alcoholic fatty liver disease and coexisting depression, anxiety and/or stress in adults: a systematic review and meta-analysis.非酒精性脂肪性肝病与成年人并存的抑郁、焦虑和/或压力:系统评价和荟萃分析。
Front Endocrinol (Lausanne). 2024 Apr 16;15:1357664. doi: 10.3389/fendo.2024.1357664. eCollection 2024.
7
Metabolic Dysfunction-Associated Steatotic Liver Disease and Metabolic Dysfunction-Associated Steatohepatitis: The Patient and Physician Perspective.代谢功能障碍相关脂肪性肝病和代谢功能障碍相关脂肪性肝炎:患者及医生视角
J Clin Med. 2023 Sep 26;12(19):6216. doi: 10.3390/jcm12196216.
8
Itemization difference of patient-reported outcome in patients with chronic liver disease.患者报告结局在慢性肝病患者中的项目化差异。
PLoS One. 2022 Feb 22;17(2):e0264348. doi: 10.1371/journal.pone.0264348. eCollection 2022.
9
Health-related quality of life in autoimmune hepatitis.自身免疫性肝炎患者的健康相关生活质量
World J Hepatol. 2021 Nov 27;13(11):1642-1652. doi: 10.4254/wjh.v13.i11.1642.
10
Non-Alcoholic Fatty Liver Disease (NAFLD) and Potential Links to Depression, Anxiety, and Chronic Stress.非酒精性脂肪性肝病(NAFLD)及其与抑郁症、焦虑症和慢性应激的潜在联系。
Biomedicines. 2021 Nov 16;9(11):1697. doi: 10.3390/biomedicines9111697.